Prognosis of Gastric Carcinoid Tumours

Digestion ◽  
1995 ◽  
Vol 56 (6) ◽  
pp. 455-462 ◽  
Author(s):  
S. Rappel ◽  
A. Altendorf-Hofmann ◽  
M. Stolte
Keyword(s):  
Gastric Carcinoid ◽  
Carcinoid Tumours

scholarly journals Subtotal Gastrectomy for Atypical Carcinoid of Stomach– A Rare Tumour

2016 ◽  
Vol 12 (2) ◽  
pp. 145-148
Author(s):  
SM Shahadat Hossain ◽  
Md Mahbubur Rahman ◽  
Md Rayhan Mahmud ◽  
Farhana Israt Jahan
Keyword(s):  
Gastrointestinal Tract ◽  
Carcinoid Tumour ◽  
Subtotal Gastrectomy ◽  
Armed Forces ◽  
Gastric Carcinoid ◽  
Rare Tumour ◽  
Carcinoid Tumours ◽  
Medical College ◽  
Gastric Carcinoids ◽  
Gastrointestinal Carcinoid

The term carcinoid was first employed by Oberndorfer in 1907 to describe a group of tumours of the gastrointestinal tract that had a relatively indolent course and that were considered to be intermediate between adenoma and carcinoma in malignant potential. Gastrointestinal carcinoid tumours are a type of cancer that form in the lining of the gastrointestinal tract originating from entero-chromaffin like (ECL) cells. Gastric carcinoid tumours are rare tumors that develop within the gastric mucosa. They can present as an isolated lesion or there can be multiple lesions. The tumours can invade locally into deeper structures of the gastrointestinal tract (GIT) wall. Solitary gastric carcinoids have a greater chance for the development of malignancy and metastases as compared to multiple gastric carcinoids due to hypergastrinemia. A 60 years old man presented with abdominal pain, vomiting and weight loss and was found to have carcinoid tumour of stomach without classic carcinoid syndrome (CS). Despite advances in the understanding of patho-physiology of carcinoid tumour its complications remain enigmatic. Early, accurate diagnosis and aggressive treatment is recommended. Journal of Armed Forces Medical College Bangladesh Vol.12(2) 2016: 145-148

Biology and management of gastric carcinoid tumours: A review

2002 ◽  
Vol 168 (12) ◽  
pp. 669-683 ◽  
Author(s):  
Irvin Modlin ◽  
Mark Kidd ◽  
Kevin Lye
Keyword(s):  
Gastric Carcinoid ◽  
Carcinoid Tumours

scholarly journals Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat.

Gut ◽  
1985 ◽  
Vol 26 (12) ◽  
pp. 1284-1295 ◽  
Author(s):  
D Poynter ◽  
C R Pick ◽  
R A Harcourt ◽  
S A Selway ◽  
G Ainge ◽  
...  
Keyword(s):  
Gastric Carcinoid ◽  
Carcinoid Tumours

scholarly journals Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours

2008 ◽  
Vol 159 (4) ◽  
pp. 475-482 ◽  
Author(s):  
Simona Grozinsky-Glasberg ◽  
Gregory Kaltsas ◽  
Chamutal Gur ◽  
Eyal Gal ◽  
Dimitrios Thomas ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Serum Gastrin ◽  
Somatostatin Analogues ◽  
Gastric Carcinoid ◽  
Carcinoid Tumours ◽  
Ecl Cells ◽  
Proliferative Effect ◽  
Ecl Cell ◽  
Long Acting

BackgroundGastric carcinoid tumours type 1 (GCA1) originate from hyperplastic enterochromaffin-like (ECL) cells secondary to hypergastrinaemia. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. We conducted a multicentre prospective study to assess the effects of long-acting SSA on hypergastrinaemia and ECL-cell proliferation in patients with GCA1.MethodsWe studied 15 patients with GCA1 treated with monthly long-acting release octreotide (LAR) (20–30 mg; n=14) or Lanreotide 90 mg (n=1) for at least 6 months. Patients had serum gastrin and chromogranin A measurements performed and biopsies taken from both tumours and surrounding mucosa before, and every 6–12 months following treatment. Sections were immunostained for neuroendocrine markers. The cell proliferation index Ki-67, intensity of staining before and after treatment and the degree of gastric wall invasion were also assessed.ResultsAll patients tolerated treatment well (mean follow-up of 18 months). In 11 patients (73%), a complete disappearance of the tumours at 1 year of treatment was observed on endoscopy, while in three patients (20%), the tumours decreased significantly in number and size. Gastrin levels normalized in 25% of patients, and were reduced by more than 80% in the remaining 75%.ConclusionsTreatment with SSAs in GCA1 leads to a substantial tumour load reduction, with a concomitant decrease of serum gastrin levels. Our data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1.

GASTRIC CARCINOID TUMOURS IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME ON LONG-TERM OMEPRAZOLE

The Lancet ◽  
1989 ◽  
Vol 333 (8641) ◽  
pp. 776-777 ◽  
Author(s):  
D. Goldfain ◽  
M.F. Le Bodic ◽  
A. Lavergne ◽  
A. Galian ◽  
R. Modigliani
Keyword(s):  
Gastric Carcinoid ◽  
Carcinoid Tumours ◽  
Zollinger Ellison Syndrome

Somatostatin Receptor Regulation of Gastric Carcinoid Tumours

Digestion ◽  
1996 ◽  
Vol 57 (1) ◽  
pp. 11-14 ◽  
Author(s):  
Laura H. Tang ◽  
Irvin M. Modlin
Keyword(s):  
Somatostatin Receptor ◽  
Gastric Carcinoid ◽  
Receptor Regulation ◽  
Carcinoid Tumours

Multiple Gastric Carcinoid Tumours Associated with Atrophic Gastritis

1990 ◽  
Vol 35 (1) ◽  
pp. 19-20 ◽  
Author(s):  
D.A. Stewart ◽  
A.R. McGowan ◽  
M.A. Roberts
Keyword(s):  
Atrophic Gastritis ◽  
Gastric Carcinoid ◽  
Carcinoid Tumours

MULTIFOCAL GASTRIC CARCINOID TUMOURS, ACHLORHYDRIA, AND HYPERGASTRINAEMIA

The Lancet ◽  
1985 ◽  
Vol 325 (8435) ◽  
pp. 951-954 ◽  
Author(s):  
R.F. Harvey ◽  
C.M. Davidson ◽  
M.J. Bradshaw ◽  
S.P. Wilkinson ◽  
P.S. Davies
Keyword(s):  
Gastric Carcinoid ◽  
Carcinoid Tumours
Sign in / Sign up

Export Citation Format

Share Document